Adaptimmune Therapeutics PLC Sponsored ADR Stock

$0.26

19.91% today

Nasdaq, Apr 04, 09:45 pm CET

ISIN

US00653A1079

Symbol

ADAP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Adaptimmune Therapeutics PLC Sponsored ADR Stock price

$0.32

-2.31 87.68% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

+0.02 6.20%

ISIN

US00653A1079

Symbol

ADAP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$82.90m
Enterprise Value	$5.50m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.03
P/S ratio (TTM) P/S ratio	0.46
P/B ratio (TTM) P/B ratio	7.00
Revenue growth (TTM) Revenue growth	194.23%
Revenue (TTM) Revenue	$178.56m
EBIT (operating result TTM) EBIT	$-63.34m
Free Cash Flow (TTM) Free Cash Flow	$-74.12m
Cash position	$151.61m
EPS (TTM) EPS	$-0.29
P/E forward	negative
P/S forward	1.89
EV/Sales forward	0.13
Short interest	3.31%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Adaptimmune Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:

5x Buy

63%

2x Hold

25%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:

Buy

63%

Hold

25%

Sell

13%

Analyst Estimates with Stock Price Targets

Financial data from Adaptimmune Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	179 179	194% 194% 100%
- Direct Costs	11 11	15% 15% 6%
Gross Profit	167 167	229% 229% 94%
- Selling and Administrative Expenses	59 59	12% 12% 33%
- Research and Development Expense	160 160	14% 14% 90%
EBITDA	-52 -52	63% 63% -29%
- Depreciation and Amortization	11 11	14% 14% 6%
EBIT (Operating Income) EBIT	-63 -63	58% 58% -35%
Net Profit	-70 -70	38% 38% -39%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Adaptimmune Therapeutics PLC Sponsored ADR Stock News

Neutral

Seeking Alpha

●

15 days ago

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Officer Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development John Lunger - VP, Manufacturing and Supply Chain Conference Call Participants Jonathan Chang - Leerink Partners Tony Butler - Ro...

Neutral

Seeking Alpha

●

5 months ago

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development Conference Call Participants Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Paul Jeng - Guggenheim Yen-Der Li - Leerink Partners Graig Suvannavejh - Mizuho Secu...

Company Profile

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Adrian Rawcliffe
Employees	506
Founded	2008
Website	www.adaptimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now